Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.

Clinical advances in hematology & oncology : H&O

Volumn 6, Issue 12, 2008, Pages 1-15

  Stone, Richard ^a   Sekeres, Mikkael ^a   Garcia Manero, Guillermo ^a   Lyons, Roger M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE; LENALIDOMIDE; THALIDOMIDE;

AGE; AGED; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONSENSUS; HUMAN; MIDDLE AGED; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RISK FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BLOOD TRANSFUSION; CLINICAL TRIALS AS TOPIC; CONSENSUS; HUMANS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS; THALIDOMIDE;

EID: 64949112734     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)